Search results
Author(s):
David Power
Added:
1 year ago
Outcomes investigating the Absorb bioresorbable vascular scaffold (BVS) in patients undergoing percutaneous coronary intervention showed more adverse ischaemic events through 5 years compared with cobalt-chromium everolimus-eluting stents. However, the period of excess risk ended at 3 years.In this short interview, Dr David Power (Mount Sinai Hospital, New York, US) discusses the final report…
View more
Author(s):
Roland R Tilz
Added:
4 months ago
AF Symposium 2026 - Prof Roland Tilz (University Heart Center Lübeck, DE) presents updated findings from the STYLE AF study evaluating vascular closure strategies in patients undergoing atrial fibrillation ablation, with implications for procedural efficiency and same-day discharge protocols.Results demonstrated clear superiority of the vascular closure device across multiple clinically relevant…
View more
LINC 25: The PATCH Study
Author(s):
Sean Lyden
Added:
1 year ago
Video
Author(s):
Added:
1 year ago
ESC HF 25 - FIVE-STAR primary outcome is neutral, though finerenone was shown to significantly reduce UACR rates with a 29% greater reduction compared to placebo.We are joined by Dr Atsushi Tanaka (Saga University, Saga, JP) to discuss the findings from FIVE-STAR, a randomized trial investigating the effects of finerenone on vascular stiffness and cardiorenal biomarkers in patients with type 2…
View more
Author(s):
Roland R Tilz
Added:
2 years ago
EHRA 24 - We are joined onsite by Dr Roland Tilz (University Heart Center, DE) to discuss the findings of the Style-AF study (NCT05563142).This prospective, randomized, controlled study aims to compare the safety and efficacy of the Perclose ProStyle suture-medicated closure device to manual compression for the treatment of hemostasis after single-shot-device pulmonary vein isolation (PVI). 125…
View more
Added:
3 months ago
Source:
Radcliffe CVRM
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to reduce major atherosclerotic cardiovascular events, but the full extent of their mechanisms is still being explored. The SEMA-VR CardioLink-15 trial investigated whether semaglutide affects the levels of circulating vascular regenerative (VR) cells, which are involved in vessel repair and may modulate atherothrombotic risk.¹…
View more
ABC Vascular
Author
Yoshi Onuma
Job title: Director of Coronary Imaging and Atherosclerosis Research
Author
Bill D Gogas
Research Area(s) / Expertise:
Job title: Editor-in-Chief, US Cardiology Review
Author
Corrado Tamburino
Research Area(s) / Expertise:
Job title: Professor and Chief of Cardiothoracic, Transplantation and Vascular Surgery Department
Author